채혈용 란셋 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the blood lancet market size was valued at USD 1.92 billion in 2025 and estimated to grow from USD 2.06 billion in 2026 to reach USD 2.92 billion by 2031, at a CAGR of 7.22% during the forecast period (2026-2031).

This report is Segmented by Product Type (Safety Lancets, Standard/Personal-use Lancets), End User (Hospitals, Blood Banks, Diagnostic Laboratories, Home Care, Others), Application (Glucose Testing, Hemoglobin Testing, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood Lancet Market Trends and Insights

Rising Diabetes and Other Chronic Disease Incidence

More than 588.7 million adults were living with diabetes in 2024, a number projected to hit 852.5 million by 2050. Untreated populations in emerging regions open a sizable addressable pool for capillary-blood monitoring, while aging demographics in developed economies multiply per-patient lancet use as comorbidities rise. Routine screening embedded in primary care pathways across OECD countries secures baseline demand, and national drive programs in India and China lift unit shipments sharply through 2030. Elevated chronic kidney and cardiovascular disease prevalence further widens the Blood lancet market as multiparameter finger-prick panels become standard follow-up diagnostics.

Growing Adoption of Point-of-Care Diagnostics

Decentralized testing models shorten turnaround times and improve therapeutic decision-making, prompting emergency rooms, ambulatory centers, and rural clinics to bulk-purchase disposable lancets. Portable analyzers that fit into backpack kits enable outreach in underserved zones, multiplying test frequency over a single patient episode. FDA fast-track pathways for at-home glucose and haemoglobin devices legitimize consumer self-testing, and private insurers increasingly reimburse home-based kits, stimulating retail-pharmacy demand. Integrated workflow benefits-fewer venipunctures, lower lab courier costs, immediate drug titration-cement the Blood lancet market as a foundational supply line for bedside diagnostics.

Infection Risk from Lancet Reuse and Poor Disposal

WHO injection-safety campaigns spotlight improper sharps disposal as a leading vector for blood-borne pathogen transmission. Compliance costs rise as clinics must provide puncture-proof bins and certified incineration agreements, eroding discretionary budgets in low-income regions. Litigation linked to healthcare-worker injuries heightens institutional risk aversion, pushing procurement toward costlier retractable models and compressing margins for basic metal-blade lines.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Reimbursement Policies in OECD Nations
2. Expansion of Blood-Donation & Screening Programs
3. Emergence of Non-Invasive Glucose-Monitoring Devices

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Safety lancets captured 60.74% of Blood lancet market size in 2025, reflecting mandatory sharps-injury prevention protocols in hospital supply chains. Institutional buyers accept higher unit prices because retractable designs lower liability exposures and workers' compensation claims. Standard or personal-use lancets, while priced 35% lower on average, deliver the fastest volume growth at an 8.05% CAGR as tele-health consults and over-the-counter diabetes packages normalize home testing routines.

Hospitals in the United States and Western Europe lock three-year supply contracts that favor ISO-certified safety models, safeguarding predictable revenue streams for market leaders. Meanwhile, e-commerce channels in Asia promote vivid color variants, ergonomic grips, and bulk refill packs that appeal to self-managing consumers. Hybrid SKUs merging protective sleeves with economical spring systems target low-to-mid income clinics, signaling future convergence within the Blood lancet market .

Complete Report Scope:

• By Product Type
  • Safety Lancets
  • Standard / Personal-use Lancets
• By End User
  • Hospitals
  • Blood Banks
  • Diagnostic Laboratories
  • Home Care
  • Others
• By Application
  • Glucose Testing
  • Haemoglobin Testing
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America's Blood lancet market size leads with a 41.88% revenue share in 2025, anchored by Medicare reimbursement for safety consumables and widespread insurance coverage for at-home diabetes supplies. Hospitals in the United States routinely adopt pain-minimized lancets to bolster patient satisfaction metrics and avert worker-safety litigation. Canadian provincial health plans deploy community-pharmacy collection hubs that distribute subsidized lancet starter kits, sustaining baseline demand.

Asia-Pacific is the fastest-growing region, projecting an 8.25% CAGR through 2031 as India's national non-communicable disease (NCD) program scales rural screening and China's urban clinics adopt tele-monitoring platforms. Public-private partnerships supply low-cost safety lancets in Indonesia's provincial health posts, while Japan's aging society pushes daily capillary testing volumes upward in long-term-care homes. Currency-hedged contract structures and local blade machining investments protect multinational suppliers from raw-material price shocks in the region.

Europe maintains stable share through robust procurement consortia such as NHS Supply Chain, which reserve tender slabs for environmentally compliant devices. Sharps-waste directives incentivize biodegradable components, opening niche opportunities for polymer innovators. South America's growth revolves around Brazilian Unified Health System upgrades and Argentina's import-substitution incentives, whereas Gulf Cooperation Council states procure premium microneedle kits aimed at medical tourists. Overall, region-specific reimbursement and regulation patterns collectively broaden the Blood lancet market while tempering one-size-fits-all product strategies.

1. Becton Dickinson & Co.
2. Roche
3. Abbott Laboratories
4. Terumo Corp.
5. B. Braun
6. Owen Mumford
7. HTL-Strefa S.A.
8. Ypsomed
9. Nipro Corp.
10. Greiner Bio-One GmbH
11. SteriLance Medical
12. Intrinsyk LLC
13. Arkray
14. Amkay Products Pvt Ltd
15. Sarstedt
16. HTD Medical Inc.
17. AgaMatrix
18. Feiner Technology Inc.
19. Sterimed (Sagard)
20. Lifescan

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising diabetes & other chronic-disease incidence
  • 4.2.2 Growing adoption of point-of-care diagnostics
  • 4.2.3 Favourable reimbursement policies in OECD nations
  • 4.2.4 Expansion of blood-donation & screening programs
  • 4.2.5 Painless microneedle innovations boosting paediatric compliance
  • 4.2.6 Home-based genetic / tele-health finger-prick kits surge
• 4.3 Market Restraints
  • 4.3.1 Infection risk from lancet reuse & poor disposal
  • 4.3.2 Emergence of non-invasive glucose-monitoring devices
  • 4.3.3 Sharps-waste environmental regulations raising costs
  • 4.3.4 Medical-grade stainless-steel supply bottlenecks
• 4.4 Value / Supply-Chain Analysis
• 4.5 Technological Outlook
• 4.6 Regulatory Landscape
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Safety Lancets
  • 5.1.2 Standard / Personal-use Lancets
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Blood Banks
  • 5.2.3 Diagnostic Laboratories
  • 5.2.4 Home Care
  • 5.2.5 Others
• 5.3 By Application
  • 5.3.1 Glucose Testing
  • 5.3.2 Haemoglobin Testing
  • 5.3.3 Others
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Overview, Market level overview, Core Segments, Financials, Strategic Info, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Becton Dickinson & Co.
  • 6.3.2 F. Hoffmann-La Roche Ltd
  • 6.3.3 Abbott Laboratories
  • 6.3.4 Terumo Corp.
  • 6.3.5 B. Braun Melsungen AG
  • 6.3.6 Owen Mumford Ltd
  • 6.3.7 HTL-Strefa S.A.
  • 6.3.8 Ypsomed AG
  • 6.3.9 Nipro Corp.
  • 6.3.10 Greiner Bio-One GmbH
  • 6.3.11 SteriLance Medical (Suzhou) Inc.
  • 6.3.12 Intrinsyk LLC
  • 6.3.13 ARKRAY Inc.
  • 6.3.14 Amkay Products Pvt Ltd
  • 6.3.15 Sarstedt AG & Co. KG
  • 6.3.16 HTD Medical Inc.
  • 6.3.17 AgaMatrix Inc.
  • 6.3.18 Feiner Technology Inc.
  • 6.3.19 Sterimed (Sagard)
  • 6.3.20 LifeScan Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment